scholarly journals Ustekinumab Biotherapy and Real-Time Psoriasis Capacitance Mapping: A Pilot Study

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Claudine Piérard-Franchimont ◽  
Gérald E. Piérard
Keyword(s):  
Pilot Study ◽  
Stratum Corneum ◽  
Treatment Efficacy ◽  
Clinical Applications ◽  
Therapeutic Effects ◽  
New Class ◽  
Water Trapping ◽  
Present Pilot Study ◽  
Quantitative Assessments ◽  
Skin Capacitance

In recent years, the treatment of moderate to severe psoriasis has benefited from the development of targeted biologicals. Assessing this new class of drugs calls for precise modalities of severity/improvement ratings of the disease. Bioengineering-driven dermometrology aims at improving objective and quantitative assessments of disease severity and treatment efficacy. Skin capacitance mapping/imaging is one of those emerging methods. Among its clinical applications, psoriasis capacitance mapping (PCM) was introduced in order to assess both skin scaliness and water trapping inside the stratum corneum (inflammatory serum deposits) on lesional skin. PCM was used for assessing the therapeutic effects of ustekinumab on target lesions of 5 psoriatic patients. The reduction in the inflammatory dampness of the stratum corneum was conveniently seen after a 1-month ustekinumab treatment. The present pilot study suggests that PCM could be used as a fast and convenient method for assessing the anti-inflammatory efficacy of ustekinumab and other biotherapies.

Radioimmunodetection of Malignant Melanoma with the 225.28S Monoclonal Antibody to HMW-MAA

1986 ◽  
Vol 25 (06) ◽  
pp. 220-224 ◽  
Author(s):  
G. L. Buraggi
Keyword(s):  
Monoclonal Antibody ◽  
Pilot Study ◽  
Malignant Melanoma ◽  
Prospective Study ◽  
Clinical Application ◽  
Multicenter Trial ◽  
Clinical Applications ◽  
Gamma Energy ◽  
A Prospective Study ◽  
Antigen Antibody

A review of the studies on the use of the antigen-antibody system HMW-MAA 225.28S in melanoma radioimmunodetection is reported. The results obtained in a pilot study (42 patients with 74 lesions), a multicenter trial (254 patients with 553 lesions) and a prospective study still outstanding (29 patients with 38 lesions) allow to consider this system as suitable for clinical application. F(ab′)2 labelled with 99mTc gave the best results in terms of positivity. Moreover this radioisotope allows the best dosimetric conditions. The gamma energy emitted by this radionuclide is particularly convenient for conventional scintillation cameras and ECT. Very good results in terms of sensitivity (70%-85%) and especially specificity (about 100%) were achieved. Possible clinical applications of the method are discussed.

scholarly journals Therapeutic Effects of the Addition of Fibroblast Growth Factor-2 to Biodegradable Gelatin/Magnesium-Doped Calcium Silicate Hybrid 3D-Printed Scaffold with Enhanced Osteogenic Capabilities for Critical Bone Defect Restoration

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 712
Author(s):  
Wei-Yun Lai ◽  
Yen-Jen Chen ◽  
Alvin Kai-Xing Lee ◽  
Yen-Hong Lin ◽  
Yu-Wei Liu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Bone Tissue ◽  
Tissue Regeneration ◽  
Calcium Silicate ◽  
Clinical Applications ◽  
Fibroblast Growth Factor 2 ◽  
Therapeutic Effects ◽  
Fibroblast Growth ◽  
3D Printed

Worldwide, the number of bone fractures due to traumatic and accidental injuries is increasing exponentially. In fact, repairing critical large bone defects remains challenging due to a high risk of delayed union or even nonunion. Among the many bioceramics available for clinical use, calcium silicate-based (CS) bioceramics have gained popularity due to their good bioactivity and ability to stimulate cell behavior. In order to improve the shortcomings of 3D-printed ceramic scaffolds, which do not easily carry growth factors and do not provide good tissue regeneration effects, the aim of this study was to use a gelatin-coated 3D-printed magnesium-doped calcium silicate (MgCS) scaffold with genipin cross-linking for regulating degradation, improving mechanical properties, and enhancing osteogenesis behavior. In addition, we consider the effects of fibroblast growth factor-2 (FGF-2) loaded into an MgCS scaffold with and without gelatin coating. Furthermore, we cultured the human Wharton jelly-derived mesenchymal stem cells (WJMSC) on the scaffolds and observed the biocompatibility, alkaline phosphatase activity, and osteogenic-related markers. Finally, the in vivo performance was assessed using micro-CT and histological data that revealed that the hybrid bioscaffolds were able to further achieve more effective bone tissue regeneration than has been the case in the past. The above results demonstrated that this type of processing had great potential for future clinical applications and studies and can be used as a potential alternative for future bone tissue engineering research, as well as having good potential for clinical applications.

Study on the therapeutic and nursing effect of thrombus targeted thrombolysis mediated by recombinant plasminogen activator modified nanoparticles on stroke patients

2021 ◽  
Vol 11 (7) ◽  
pp. 1024-1030
Author(s):  
Li Zhang ◽  
Miao Xu ◽  
Min Zhu ◽  
Andong Liu ◽  
Fenghua Zhao
Keyword(s):  
Drug Therapy ◽  
Plasminogen Activator ◽  
Survival Rates ◽  
Clinical Applications ◽  
The Self ◽  
Therapeutic Effects ◽  
Stroke Patients ◽  
Traditional Treatment ◽  
Thrombolytic Drug ◽  
Tissue Plasminogen

Tissue plasminogen activator (rt-PA) is a thrombolytic drug used for the treatment of stroke. However, it has a short half-life and a high risk of complications of cerebral hemorrhage, which complicates its use in clinical applications. In this study, polyethylene glycol and polycaprolactone were used as nano-carriers in the development of new nano-drug-recombinant plasminogen activator modified nanoparticles (PEG-PCL@rt-PA) loaded with rt-PA. Following treatment, the patients received with either conventional nursing or continuous nursing. Compared with traditional treatment and nursing, the nanoparticles had stronger thrombolytic and therapeutic effects, significantly improved the self-care recovery rate of patients, and reduced the occurrence of complications. This new mode of PEG-PCL@rt-PA drug therapy combined with continuous nursing is expected to improve the recovery and survival rates of stroke patients.

Time-Series Analysis of Continuous Glucose Monitoring Data to Predict Treatment Efficacy in Patients with T2DM

2021 ◽  
Author(s):  
Li Li ◽  
Jie Sun ◽  
Liemin Ruan ◽  
Qifa Song
Keyword(s):  
Time Series ◽  
Time Series Analysis ◽  
Continuous Glucose Monitoring ◽  
Treatment Efficacy ◽  
Treatment Effects ◽  
Glucose Monitoring ◽  
Therapeutic Effects ◽  
Time Series Clustering ◽  
Glucose Lowering ◽  
Series Analysis

Abstract Context There is a challenge to predict treatment effects in patients with T2DM. Objective To assess and predict treatment effects in patients with T2DM through time-series analysis of continuous glucose monitoring (CGM) measurements. Design We extracted and clustered the trend components of CGM measurements to generate representative time-series profiles, which were used as a predictor of treatment effects in groups of patients. Setting and Participants We recruited 111 outpatients with T2DM at Ningbo City First Hospital. Intervention The patients underwent CGM measurement for 14 days at the beginning of glucose-lowering treatment. Main Outcome Measures HbA1c and FPG were obtained at the beginning and 6-month of treatment. Results 111 patients each had 960 –1344 CGM measurements for 14 days at 96 measurements per day. The patients were classified into three groups according to the profiles of trend components of CGM observed values by time-series clustering method, including decreasing (47 patients), increasing (26 patients), and unchanged (38 patients) profiles. After six-month glucose-lowering treatment, FPG declined from 10.2 to 6.8 mmol/L (a decline of 3.5 mmol/L) in the decreasing group, from 8.9 to 9.2 mmol/L (a rise of 0.3 mmol/L) in the increasing group, and from 8.4 to 7.5 mmol/L (a decline of 0.9 mmol/L). The changes of HbA1c were 2.2%, 0.2%, and 0.9% for the three groups (P<0.01), respectively. Conclusions Clustering of the trend components of CGM data generates representative CGM profiles that are predictive of six-month therapeutic effects for T2DM.

Reliability of the Multi-Dimensional Voice Program for the Analysis of Voice Samples of Subjects With Dysarthria

1999 ◽  
Vol 8 (2) ◽  
pp. 129-136 ◽  
Author(s):  
Ray D. Kent ◽  
Houri K. Vorperian ◽  
Joseph R. Duffy
Keyword(s):  
Computer Program ◽  
Clinical Assessment ◽  
Quantitative Information ◽  
Speech Disorders ◽  
Clinical Applications ◽  
Automatic Analysis ◽  
Acoustic Parameters ◽  
Assessment And Treatment ◽  
Computer Based ◽  
Quantitative Assessments

Computer-based analysis systems are increasingly available for the clinical assessment of speech and voice functions. These systems have the potential to provide immediate quantitative information to assist clinical assessment and treatment. The Multi-Dimensional Voice Program (MDVP) is a computer program that can calculate as many as 33 acoustic parameters from a voice sample. The MDVP appears to have potential for rapid quantitative assessments of voice in both research and clinical applications. This report evaluates the robustness and reliability of MDVP for vocal analyses of 32 individuals with dysarthria of various etiologies. It is concluded that the reliability is generally very good and that MDVP has potential as a tool for the semi-automatic analysis of voice samples in dysarthria. Some parameters appear to hold particular value in the description of voice qualities in these speech disorders.

Breviscapine: A Review on its Phytochemistry, Pharmacokinetics and Therapeutic Effects

2021 ◽  
pp. 1-29
Author(s):  
Luan Wen ◽  
Ting He ◽  
AXiang Yu ◽  
Siqi Sun ◽  
Xiang Li ◽  
...  
Keyword(s):  
Active Component ◽  
Drug Research ◽  
Preparation Method ◽  
Pharmacological Action ◽  
Structural Features ◽  
Clinical Applications ◽  
Pharmacokinetic Studies ◽  
Therapeutic Effects ◽  
Comprehensive Understanding ◽  
Pharmacological Activities

Breviscapine is one of the extracts of several flavonoids of Erigeron breviscapus. Scutellarin is the main active component of breviscapine, and the qualitative or quantitative criteria as well. Scutellarin and its analogs share a similar skeleton of the flavonoids. Breviscapine has been widely used in the treatment of cerebral infarction and its sequelae, cerebral thrombus, coronary heart disease (CHD), and angina pectoris. Breviscapine has a broad spectrum of pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, decreasing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation, and thrombosis formation, etc. In addition, breviscapine and its analogs have significant value for drug research and development because of the superiority of those significant bioactivities. Furthermore, an increasing number of pharmacokinetic studies have explored the mechanism of scutellarin and its analogs. To provide a comprehensive understanding of the current research on breviscapine, scutellarin, and the analogs, the structural features, distribution situation, preparation method, content determination method, clinical applications, pharmacological action as well as pharmacokinetics are summarized in the present review.

Psychosexual Fixation and Defense Mechanisms in a Sample of Young Japanese Women: A Preliminary Study

2010 ◽  
Vol 107 (1) ◽  
pp. 79-86 ◽  
Author(s):  
Tamiko Mogami
Keyword(s):  
College Students ◽  
Pilot Study ◽  
Defense Mechanisms ◽  
Japanese Women ◽  
Female College Students ◽  
Female College ◽  
Young Japanese Women ◽  
Preliminary Study ◽  
Present Pilot Study

The present pilot study examined psychosexual fixations and defense mechanisms in a sample of young Japanese women. The Lexical Rorschach count and the Defense Mechanisms Inventory were administered to 24 female college students. Sadism on the Lexical Rorschach count was positively correlated with Reversal of Affect. Phallic fixation on the Lexical Rorschach count was positively correlated with Projection. Psychoanalytic hypotheses about the associations between psychosexual fixations and defense mechanisms were partially confirmed.

scholarly journals What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Qixin Xie ◽  
Rui Liu ◽  
Jia Jiang ◽  
Jing Peng ◽  
Chunyan Yang ◽  
...  
Keyword(s):  
Umbilical Cord ◽  
Lupus Erythematosus ◽  
Heart Diseases ◽  
Clinical Applications ◽  
Human Umbilical Cord ◽  
Therapeutic Effects ◽  
Main Body ◽  
Mesenchymal Stem Cell Transplantation ◽  
Cord Injury ◽  
The Impact

Abstract Background Human umbilical cord mesenchymal stem cells (HUC-MSCs) present in the umbilical cord tissue are self-renewing and multipotent. They can renew themselves continuously and, under certain conditions, differentiate into one or more cell types constituting human tissues and organs. HUC-MSCs differentiate, among others, into osteoblasts, chondrocytes, and adipocytes and have the ability to secrete cytokines. The possibility of noninvasive harvesting and low immunogenicity of HUC-MSCs give them a unique advantage in clinical applications. In recent years, HUC-MSCs have been widely used in clinical practice, and some progress has been made in their use for therapeutic purposes. Main body This article describes two aspects of the clinical therapeutic effects of HUC-MSCs. On the one hand, it explains the benefits and mechanisms of HUC-MSC treatment in various diseases. On the other hand, it summarizes the results of basic research on HUC-MSCs related to clinical applications. The first part of this review highlights several functions of HUC-MSCs that are critical for their therapeutic properties: differentiation into terminal cells, immune regulation, paracrine effects, anti-inflammatory effects, anti-fibrotic effects, and regulating non-coding RNA. These characteristics of HUC-MSCs are discussed in the context of diabetes and its complications, liver disease, systemic lupus erythematosus, arthritis, brain injury and cerebrovascular diseases, heart diseases, spinal cord injury, respiratory diseases, viral infections, and other diseases. The second part emphasizes the need to establish an HUC-MSC cell bank, discusses tumorigenicity of HUC-MSCs and the characteristics of different in vitro generations of these cells in the treatment of diseases, and provides technical and theoretical support for the clinical applications of HUC-MSCs. Conclusion HUC-MSCs can treat a variety of diseases clinically and have achieved good therapeutic effects, and the development of HUC-MSC assistive technology has laid the foundation for its clinical application.

Sign in / Sign up

Export Citation Format

Share Document